
CLAIMS

1. An antisense oligomer compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof,


where each Nu is a nucleobase which taken together forms a targeting sequence;

T is selected from:



; ; and ; and

G is a cell penetrating peptide ("CPP") and linker moiety selected from:



-C(O)CH_2NH-CPP-R^a, and ,

~~wherein the CPP is attached to the linker moiety by an amide bond at the CPP carboxy terminus, R^a is attached to the CPP amino terminus by an amide bond wherein R^a is selected from H, acetyl, benzoyl, and stearoyl, and the CPP is selected from SEQ ID NOS: 5 – 21, and~~


~~wherein the targeting sequence is selected from:~~

~~a) SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) wherein Z is 23; and~~


~~b) SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) wherein Z is 23.~~

~~2. The antisense oligomer compound of claim 1, wherein G is selected from SEQ ID NOS: 24 OR 25.~~


~~3. The antisense oligomer compound of claims 1 or 2, wherein T is~~



~~4. The antisense oligomer compound according to any one of claims 1-3, wherein CPP R^a is selected from:~~




,




,

~~and~~



~~5. The antisense oligomer compound according to any one of claims 1-3,~~




~~wherein the CPP-R[a] is .~~

~~6. The antisense oligomer compound according to any one of claims 1-5, wherein R[a] is acetyl.~~

~~7. The antisense oligomer compound according to any one of claims 1-6, wherein the targeting sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.~~

~~8. The antisense oligomer compound according to any one of claims 1-6, wherein the targeting sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.~~

~~9~~1. An antisense oligomer compound of formula (III):



(III) ,

or a pharmaceutically acceptable salt thereof, wherein:

each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) selected from:

a) SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) wherein Z is 23; and


b) SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) wherein Z is 23;

wherein R^a is acetyl.

~~10~~2. The antisense oligomer compound of claim ~~9~~1, wherein the target sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.

~~11~~3. The antisense oligomer compound of claim ~~9~~1, wherein the target sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.


~~12~~4. The antisense oligomer compound of claim ~~9~~1, wherein the antisense oligomer compound is a compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) wherein the targeting sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.


~~135~~. The antisense oligomer compound of claim ~~91~~, wherein the antisense oligomer compound is a compound of formula (IV):



(IV)


or a pharmaceutically acceptable salt thereof, wherein each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) wherein the targeting sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.

~~14~~6. An antisense oligomer compound, or a pharmaceutically acceptable salt thereof, selected from:




(V a)

; and



.


~~157~~. The antisense oligomer compound of claim ~~146~~, wherein the antisense oligomer compound is:



(V a)

.


~~168~~. The antisense oligomer compound of claim ~~146~~, wherein the antisense oligomer compound is:



(V b)


.

~~179~~. An antisense oligomer compound, or a pharmaceutically acceptable salt thereof, selected from:



(VI a)

; and



(VI b)

.

~~18~~10. The antisense oligomer compound of any one of claims ~~1-17~~1-9, wherein the antisense oligomer compound is a pharmaceutically acceptable salt of 0.6 HCl.

~~19~~11. A pharmaceutical composition, comprising an antisense oligomer compound according to any one of claims ~~1-18~~1-10 and a pharmaceutically acceptable carrier.

~~20~~12. Use of an antisense oligomer compound according to any one of claims ~~1-18~~1-10 or the pharmaceutical composition of claim ~~19-~~11 in the manufacture of a medicament for the treatment of Hutchinson- Gilford progeria syndrome (HGPS).